Indomethacin reduces proteinuria in passive Heymann nephritis in rats. Indomethacin has been used to lower proteinuria in human glomerular diseases with controversial results. The mechanism of indomethacin beneficial effects has not been established. A possible explanation is that indomethacin reduces proteinuria by inhibiting the synthesis of renal prostaglandins (PGs); however, appropriate studies to address this issue have never been done. The objectives of the present study were: a) to investigate whether indomethacin influences protein excretion in an experimental model of immunologically-mediated glomerular disease; b) to establish if the possible favorable effect of indomethacin on proteinuria is related to a reduction in glomerular filtration rate (GFR); c) to establish the possible association between the antiproteinuric effect of indomethacin and its inhibitory effect on arachidonic acid (AA) metabolites of renal or extrarenal origin; and d) to further investigate the relationship between proteinuria and renal thromboxane (Tx) synthesis previously demonstrated in experimental models of nephrotoxic nephritis and adriamycin (ADR) nephrosis. To this purpose we used an experimental immune-complex disease, passive Heymann nephritis (PHN) which was induced in the rat by a single intravenous (i.v.) injection of heterologous serum directed against a brush border component (gp 330 antigen). Indomethacin at a dose of 6 mg/kg intraperitoneally (i.p.) administered for four consecutive days to PHN animals during the period of heavy proteinuria, effectively reduced urinary protein excretion. The reduction in proteinuria does not appear to be a consequence of a reduction in GFR as documented by inulin clearance. Glomerular synthesis and urinary excretion of vasodilatory prostacyclin (PGI2) and PGE2 were decreased or unchanged in PHN animals in respect to control animals. At variance, isolated glomeruli from rats with PHN studied 16 days after anti-gp 330 serum injection, when animals were heavily proteinuric, generated significantly more TxB2, the stable breakdown product of TxA2, than normal glomeruli. Urinary excretion of TxB2 was also significantly higher in rats with PHN than in normal rats. Indomethacin reduced the urinary TxB2 excretion by 74%. The administration of a selective Tx.synthase inhibitor UK-38,485 at a dose fully inhibiting platelet TxA2 synthesis only partially (around 40%) inhibited urinary excretion of TxB2 and did not reduce urinary protein excretion. These results may provide the experimental basis for the clinical observation that indomethacin has an antiproteinuric effect in humans.
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Indomethacin was widely used between 60's and 70's in the treatment of proteinuric glomerular diseases, with controversial results [1] [2] [3] [4] . No convincing explanations have been provided © 1987 by the International Society of Nephrology for the antiproteinuric effect of indomethacin in man. Since indomethacin's favorable effect on proteinuria was more pronounced in condition of sodium depletion, an inhibitory effect on renin release was proposed [5] . An alternative explanation was that the reduction of proteinuria following indomethacin is a consequence of the reduction in glomerular filtration rate (GFR) [6] . The theory that indomethacin's favorable effect on proteinuria depends on its inhibitory effect on the enzyme cyclooxygenase, with the consequent suppression of eicosanoid synthesis, has also been proposed [6] . However, measurements of appropriate biochemical parameters are lacking both in experimental animals or humans given indomethacin to reduce proteinuria.
The present work was designed to investigate if indomethacin influences proteinuria in an experimental model of immunologically-mediated glomerular damage. We also wanted to establish if the possible favorable effect of indomethacin on protein excretion has to be attributed to a reduction in GFR or to an inhibition of eicosanoid synthesis of renal or extrarenal origin.
To this purpose we used an experimental immune-complex disease, passive Heymann nephritis (PHN). PHN can be induced in rats by injection of heterologous antibodies directed against antigen(s) present along the brush border (BB) of proximal tubules of the kidney [7, 8] . Immunofluorescence (IF) microscopy reveals diffuse, finely granular deposits of IgG and complement along the outer portion of the glomerular capillary wall, and electron microscopy (EM) demonstrates deposits of electron-dense material exclusively in the subepithelial space [7, 8] . Abnormal proteinuria and glomerular immune complex deposition are the most common findings of this model [9, 10] , which resembles membranous nephropathy in humans. It was initially believed that PHN was due to glomerular deposition of circulating immune complexes constituted by BB antigens and their respective antibodies [8] . More recently, evidence has converged to indicate that PHN is due to an in situ formation of immune complexes between a BB related antigen expressed on glomerular visceral epithelial cells and its respective circulating antibody [9, [11] [12] [13] . Several studies were devoted to establish the identity of the antigen(s) involved in the glomerular immune reaction. Recently, Kerjaschki and Farquhar [14] , starting from a purified BB preparation, have isolated a glycoprotein of molecular weight of 330,000 dalton (gp 330) localized in the coated pits of glomerular epithelial cells.
We have used an antiserum specifically directed against the gp 330 BB antigen to induce PHN in rats.
Methods
Purification of gp 330 antigen The gp 330 antigen was prepared according to Ronco et al [15] by afilnity chromatography from sodium deoxycholate (DOC)-solubilized BB on Sepharose 4 B (Pharmacia, Velizy, France) covalently linked to a mixture of three monoclonal antibodies: Fl/12, F3/28 and F31237. Ten milligrams of BB membrane vesicles were solubilized by incubation for one hour at room temperature in 1.25% DOC in 50 mr'i Tris HC1, pH 8.6, containing 1 mri phenylmethylsullonyl fluoride. The supernatant was dialyzed overnight at 4°C against 0.1% DOC in Tris buffer, ultracentrifuged at 100,000 x g and incubated overnight with 2 ml of antibody-coupled Sepharose 4 B. After extensive washing, bound antigen was eluted at alkaline pH according to Parham [16] and was dialyzed against phosphate buffered saline.
Preparation of anti-gp 330 antibodies Rabbits were immunized with 50 jig of gp 330 emulsified in complete Freund's adjuvant. Four immunizations at three week intervals were performed. The antisera were tested by indirect IF. When intravenously (i.v.) injected in rats the serum induced PHN. The inducing serum was 0.5 ml, containing approximately 500 jig of anti-gp 330 antibody.
Experimental design Sprague-Dawley, CD-COBS male rats (Charles River Italia S.p.A., Calco, Italy) weighing 275 to 300 g at the start of the experiment were used. Animals were fed a standard rat chow (Altromin Rieper, Vandoies, Italy) and had free access to tap water. PHN was induced in 48 non-anesthetized rats by a single i.v. injection of 0.5 ml of heterologous anti-gp 330 serum through the tail vein. The following experimental groups were considered:
Heterologous phase. Eight rats were studied in the heterologous phase of the disease and sacrificed two days after anti-gp 330 serum injection. At this time protein excretion was measured and thromboxane B2 (TxB2), the stable breakdown product of TxA2, 6-keto-PGF1a, the stable hydrolysis product of prostacyclin (PGI2) and PGE2 production, were studied in glomerular preparations and urinary samples.
Autologous phase. Eight rats were studied during the autologous phase of the disease and sacrificed 16 days after PHN induction. Twenty-four hour protein excretion was measured at days 0, 2, 6, 9, 12 and 16 after anti-gp 330 serum injection.
Glomerular production and urinary excretion of TxB2, 6-keto-PGF1,. and PGE2, serum TxB2 production and serum creatinine were studied at the end of the experimental period.
Proteinuria improvement. In order to establish whether and by which mechanisms indomethacin could ameliorate proteinuria, 12 days after PHN induction eight rats were intraperitoneally injected with indomethacin (Liometacen, Chiesi Farmaceutici, S.p.A., Parma, Italy) 3 mg/kg bid for four days. The animals were sacrificed 16 days after anti-gp 330 serum injection. Proteinuria and urinary excretion of TxB2, 6-ketoPGF1a and PGE2 were studied before and after indomethacin treatment. Serum TxB2 production and serum creatinine were measured at the end of the experimental period.
Suppression of TxB2 excretion. Sixteen PHN rats were used to determine whether a selective inhibition of Tx synthesis had the same favorable effect of indomethacin in reducing protein excretion and to further investigate a possible relationship between Tx and proteinuria. Twelve days after PHN induction eight rats were i.p. injected for four consecutive days with the Tx synthase inhibitor UK-38,485 at the daily dose of 20 mg/kg divided in three administrations, and eight rats were i.p. injected with an higher dose of UK-38,485 (40 mg/kg divided in three administrations for the same period of time) in the attempt to fully suppress the urinary excretion of TxB2. All the animals were sacrificed 16 days after the PHN induction. Proteinuria and urinary excretion of TxB2, 6-keto-PGF,a and PGE2 were studied before and after UK-38,485 treatment. Serum TxB2 production and serum creatinine were measured at the end of the experimental period.
Clearance studies. Eight PHN rats were used for renal clearance studies. Four PHN rats were treated with indomethacm (3 mg/kg i.p. bid) from day 12 to day 16 after anti-gp 330 serum injection, and four PHN rats received the solvent in which indomethacin was dissolved, for the same period of time. Inulin clearance was performed at day 16 after PHN induction in all animals.
Controls. Eight normal rats were used as controls. Twentyfour-hour urine samples were collected in metabolic cages. Proteinuria was determined by the modified Coomassie blue G dye-binding assay for proteins [17] . Urine samples for Tx and PG measurement were immediately frozen after collection and stored at -20°C until the extraction and the radioimmunossay (RIA) were performed. Blood samples for determination of serum TxB2 and serum creatinine were collected by intracardiac puncture from ether anesthetized animals at the end of the experimental period. Platelet TxB2 production in response to endogenous thrombin was studied by letting multiple I ml aliquots of whole blood to clot at 37°C for 60 minutes, as previously described [18] . The sera were frozen and kept at -20°C until assayed. Serum creatinine was determined by alkaline picrate method [19] .
Histological studies Renal tissue specimens were obtained from kidney biopsies. For light microscopy (LM), fragments of the cortex were fixed in Dubosq-Brazil fluid (80% alcohol, 150 ml; formol, 60 ml; acetic acid, 15 ml; picric acid, 1 g) and embedded in paraffin. Sections of 2 iim were stained with Masson's trichrome, hematoxylin and eosin, periodic acid staining (periodic acid-Schifi), and Wilder's reticulin. For IF, sections of 3 jim of fresh frozen tissue were cut in a cryostat and were incubated with fluoresceinated sera raised against rabbit IgG and rat IgG and C3 (N.L. Cappel Laboratories Inc., West Chester, Pennsylvania, USA). The sections were then washed in phosphatebuffered saline for 45 minutes at room temperature, embedded in buffered glycerine (pH 7.2), and examined in a Leitz microscope under ultraviolet light using a Ploem epifluorescence illuminator system. For EM, small pieces of the cortex were fixed with phosphate-buffered 2.5% glutaraldehyde (pH 7.2) for four hours, then rinsed in 0.2 M cacodylate buffer (pH 7.4). Subsequently the samples were postfixed in 1% osmium tetroxide at 4°C for one hour, washed in buffer, and immersed in 0.5% Veronal uranyl acetate. Samples were then dehydrated through graded alcohol and embedded in Spurr resin. Ultrathin sections (60 to 80 nm) were cut on an LKB V ultramicrotome (LKB Instruments, Milan, Italy) and examined with a Zeiss EM 109 (Carl Zeiss, Oberkochen, West Germany).
Isolation and incubation of glomeruli Treated and control rats were anesthetized with ether and a cannula was inserted into the lower aorta. Subsequently, the aorta was clamped above the renal arteries, the renal veins were cut, and the kidneys were perfused with 60 to 80 ml of Krebs-Ringer phosphate buffer (KRB) with the following composition: 120.29 mri NaC1, 4.82 mivt KCI, 1.21 mri MgSO4, 2.57 mM CaCl2 and 15.6mM phosphate buffer (pH 7.4). When kidney surfaces were completely blanched, the kidneys were removed and immediately immersed in ice cold KRB. All subsequent preparative steps were performed at 4°C. The renal capsules were removed and the cortex was separated from the medulla. The cortical segments of the kidneys from animals of the same group were pooled and finely minced into 1 to 2 mm fragments. The glomeruli were separated from residual cortical tissue by passing the homogenate through different size sieves and pressing the preparation through a 106 m sieve to exclude the tubules, and a 75 m sieve to retain the glomeruli. The sieved tissue, suspended in KRB pH 7.4, was passed through a 25-gauge needle and centrifuged at 140 x g for 120 seconds. The supernatant was discarded, the pellet resuspended in the same buffer solution, passed again through the needle, and centrifuged. The purity of isolated glomeruli was determined microscopically by counting the number of glomerular and nonglomerular particles suspended in a given volume. The final pellet consisted of decapsulated glomeruli with less than 2% tubular contamination. EM of the normal isolated glomeruli showed well preserved ultrastructure with intact endothelial lining, basement membranes, and distinct epithelial foot-processes. The glomeruli of treated and control rats were always prepared in parallel.
Freshly prepared glomeruli from control and treated rats were resuspended in I ml of KRB at 37°C in room atmosphere in a Dubnoff shaking bath (120 cycles/mm). Incubation was stopped after 60 minutes by centrifugation at 3,000 x g for five minutes, and the supernatant of each tube was collected and frozen until Tx measurement. Protein concentration was determined according to the method of Lowry et al [201 with bovine serum albumin as a standard. The concentration of glomerular proteins ranged between 300 and 700 igIml.
Urine extraction Because urine differs from other biological fluids in that it contains the most complex mixture of arachidonic acid (AA) metabolites, in addition to a number of factors that may possibly interfere with any antigen-antibody reaction, we submitted urinary samples to extraction and silicic acid chromatography before RIA. Six thousand dpm of 3H-TxB2 (New England Nuclear Boston, Massachusetts, USA, 113 Ci/mmol) or 3H-6-keto-PGFIa (New England Nuclear, 130 Cu mmol) or 3H-PGE2 (New England Nuclear, 180 Ci/mmol) in 1 ml of 50 m phosphate buffer pH 7.4 were added to 3 ml aliquots of urine to serve as a tracer during extraction and purification. Urine was acidified to pH 3.5 with formic acid (99%), and applied to a disposable octadecyl (C18) column (Sep-pak, Millipore, Mildford, Massachusetts, USA) previously washed with 10 ml methanol and 10 ml water. The column was eluted with 10 ml of water, 10 ml of n-hexane and 10 ml of ethylacetate. The ethylacetate fraction was taken to dryness in a rotary evaporator at 37°C. Silicic acid (Merck, Darmstadt, Federal Republic of Germany), 0.5 g, was dissolved in 4 ml benzene/ethylacetate (60:40) (solvent 1) and added to a small glass column (6 x 0.7 cm). The column was washed with 4 ml benzene/ethylacetate/methanol (60:40:20) (solvent 2) and 1.5 ml of solvent 1. For 6-keto-PGF1 , 4 ml of solvent 2a were used (benzene/ethylacetate/methanol 60:40:30) instead of solvent 2. The extracted residue was resuspended in 0.2 ml benzene/ethylacetate/methanol (60:40: 10) (solvent 3) and 0.8 ml solvent 1 was added. The mixture was applied to the column, and PG fractions were eluted with 4 ml of solvent 1 (fraction I: PGA and PGB) and 8 ml of solvent 2 for TxB2 and PGE2, or 8 ml solvent 2a for 6-keto-PGF1a (fraction II: PGE and PGF). Fraction II was collected and taken to dryness at 37°C, redissolved in 3 ml 50 mM phosphate buffer pH 7.4 and an aliquot was analyzed for radioactivity. The recovery of the radioactive tracers for all the compounds, which ranged from 60 to 75%, was utilized to correct the measured endogenous concentrations of TxB2, 6 -keto-PGF1a and PGE2.
Radioimmunoassay
Unextracted supernatants of glomerular preparations and extracted urinary samples were assayed for TxB2, the stable breakdown product of TxA2, 6-keto-PGF1a, the stable hydrolysis product of PGI2, and PGE2. Serum samples were assayed for TxB2. All the samples were diluted in 50 m phosphate buffer (pH 7.4) before RIA. Unextracted glomerular supernatants were diluted 1:6 to 1:10 for TxB2, 1:50 to 1:250 for 6-keto-PGF12 and 1:100 to 1:250 for PGE2. Extracted urinary samples were diluted 1:6 to 1:40 for TxB2, 1:20 to 1:100 for 6-keto-PGF1a and 1:50 to 1:500 for PGE2. Serum samples were assayed for TxB2 at a final dilution of 1:3000 to 1:10.000. Five thousand dpm of 3H-TxB2, or 3H-6-keto-PGF1a or 3H-PGE2 and amounts of specific rabbit antibodies sufficient to bind 40% of the tritiated compounds were incubated 16 to 24 hours at 4°C in a final volume of 1.5 ml to each assay tube. Anti-TxB2, anti-6-keto-PGF1,. and anti-PGE2 antibodies were used at a final dilution of 1:250,000, 1:300,000 and 1:50,000, respectively. Anti-PGE2 antiserum was provided by Professor Carlo Patrono, Università Cattolica del Sacro Cuore, Roma, Italy. Separation of free from antibody-bound tritiated compounds was obtained by rapid addition of 10 mg of uncoated charcoal (Norit A). Immediately before the addition of charcoal, 0.1 ml of human PG-free plasma was added to each tube in order to prevent the adsorption to charcoal of antibody-bound PGs. One tenth ml of charcoal suspension in 0.02 M phosphate buffer pH 7.4 (100 mg/mI) was then added to each sample, which was shaked by a vortex mixer and centrifuged for 20 minutes at 2,000 x g at 4°C. Supernatant solution containing antibody-bound Tx or PGs was decanted directly into 8 ml of Instagel II (Packard Instrument Co. Inc., Downers Grove, Illinois, USA). Radioactivity of samples was counted in a liquid scintillation counter (LS 1800 model, Beck-man, Irvine, California, USA). The smallest concentration that could be measured with 95% confidence was 2 pg/mI for all the antisera; consequently the detection limit in glomerular preparations was 12 pg/mI for TxB2, 100 pg/mI for 6-keto-PGF1a and 200 pg/mI for PGE2; in urinary samples was 12 pg/mi for TxB2, 40 pg/mI for 6-keto-PGF1 and 100 pg/mi for PGE2; in serum samples was 6 ng/ml for TxB2. Results were expressed as ng/mg protlhr of TxB2,6-keto-PGF1 and PGE2 for glomerular preparation, ng/ml of TxB2 for serum and nglday of TxB2, 6-keto-PGF1 and PGE2 for urine. The cross-reactivity at 50% displacement of other arachidonate metabolites with antisera were as follows: TxB2 antiserum: 2,3-dinor TxB2, 10.5%; 6-keto-PGF1, 0.004%; PGE2, 0.008%; PGD2, 0.018%; PGF2a, 0.020%; AA, 0.004%. 6-ketoPGF1, antiserum: TxB2, 0.006%; PGE2, 0.37%; PGD2, 0.09%; PGF2a, 3.0%; AA, 0.0023%; PGE2 antiserum: TxB2, 0.015%; 6-keto-PGF1a, 0.014%; PGD2, 0.11%; PGF2., 1.0%.
Validation of RIA measurements was obtained by several independent criteria: dilution and recovery studies; comparison among multiple antisera; characterization of the chromatographic pattern of distribution of the extracted PG and Tx-like immunoreactivity on thin-layer chromatography; comparison with gas chromatographic mass spectrometric determinations.
Renal clearance studies
Rats were anesthetized by intraperitoneal injection of Pentothal (50 mg/kg body wt). Surgical preparation consisted of tracheostomy, cannulation of femoral artery and vein, and placement of a large-bore polyethylene tube into the bladder through a small suprapubic incision. A heated table maintained body temperature at 37°C. Arterial blood pressure was continuously monitored throughout the experiment directly from the femoral artery by a polyethylene tube (PE-50), connected to a pressure transducer and a carrier amplifier (Battaglia Rangoni, Bologna, Italy). GFR was measured by the clearance of inulin (E. Merck, Darmstadt, FRG). Five g inulin and 900 mg NaCI were dissolved in 100 ml distilled water. Two ml of this saline solution containing 5% inulin were infused in the femoral vein as a priming load, followed by constant infusion of the same solution via a syringe pump at 2 mI/hr. A 40 minute equilibration period was allowed after surgery and initiation of infusion in order to attain constant plasma levels of inulin. Clearance periods, 30 minutes each, were performed in triplicate. At the midpoint of each period 100 p1 blood samples were obtained from the femoral artery and plasma was separated by centrifugation. Urine samples were collected from the bladder in preweighed vessels. Plasma and urine inulin was determined by methods previously described [21] modified for microliter samples.
Results
Time course of proteinuria and histological findings After a single i.v. injection of heterologous anti-gp 330 serum, all treated animals developed the nephritis. Proteinuria started five to six days after anti-gp 330 serum injection, reached statistically significant values (P < 0.01) after 12 days when compared to basal level (219 79 versus 22.08 7.48 mg/day), and persisted during the following days (Fig. 1) .
LM showed no abnormalities in the glomeruli of rats injected with anti-gp 330 serum during the heterologous phase of the disease. IF 48 hours after i.v. injection of anti-gp 330 revealed clear, diffuse granular deposition of rabbit IgG along the glomerular capillary wall. By EM few electron-dense deposits were present on the outer aspect of glomerular basement membrane. In the autologous phase at LM glomeruli showed only a moderate swelling of visceral epithelial cells. In the lumens of many distal tubules, eosinophilic proteinaceous casts were seen. By IF a strong granular deposition of rabbit IgG and rat IgG and C3 was detected along the glomerular capillary walls. By EM numerous electron-dense deposits were evident in the lamina rara externa with some areas of epithelial foot-process fusion.
Glomerular Tx and PG synthesis in rats with PHN

Statistical analysis
All the results are expressed as the mean so. Data were analyzed using one way analysis of variance. Significance level of differences between groups was established using Duncan's multiple range test or Dunnett's test. Protein excretion and urinary Tx and PG excretion values in PHN animals before and after indomethacin or UK-38,485 treatment were analyzed using paired Student's t-test. Glomerular TxA2 synthesis was measured as generation of immunoreactive TxB2 in the supernatant of isolated glomeruli. Glomerular TxB2 production in eight rats studied two days after the injection of anti-gp 330 serum, before they developed proteinuria, was not different from control animals (0.15 0.04 v. 0.21 0.05 ng/mg prot/hr, Fig. 2 ). In contrast, glomerular TxB2 production in PHN animals studied in the phase of heavy proteinuria (16 days after anti-gp 330 injection) was significantly (P < 0.01) higher (0.47 0.10 ng/mg prot/hr) (Fig. 2) . Glomer- Fig. 2 ). In contrast, urinary excretion of TxB2 in rats with PHN studied 16 days after induction of the disease was significantly (P <0.05) higher (34.09 8.19 ng/day, Fig. 2 ). Urinary excretion of 6-keto-PGF1a and PGE2 was not significantly modified in rats with PHN studied two and 16 days after anti-gp 330 serum injection ( Table 1) .
Treatment of PHN rats with indomethacin or UK-38,485 and effect on platelet TxA2 synthesis PHN rats during the period of heavy proteinuria were treated with either the cyclooxygenase inhibitor indomethacin or the Tx-synthase inhibitor UK-38,485. Twelve days after anti-gp 330 serum injection, eight rats were given indomethacin 6 mg/kg i.p.
for four days, eight rats received the Tx-synthase inhibitor at the daily dose of 20 mg/kg i.p. for four days, and eight rats received the Tx-synthase inhibitor at the daily dose of 40 mg/kg i.p. for the same period of time. Serum TxB2 production was 22 .66 5.42 ng/mI for the indomethacin treated group, 54.50 22.15 ng/ml for the group treated with 20 mg/kg of UK-38,485 and 27.80 6.56 ng/ml for the group treated with 40 mg/kg of UK-38,485. Both inhibitors were effective in reducing significantly (P < 0.01) serum TxB2 production of PHN animals as compared to both control and untreated PHN rats studied at the corresponding time (224.93 57.25 and 234.66 58.41 ng/ml, respectively).
Effect of indomethacin on proteinuria and urinary excretion of AA metabolites In PHN rats given indomethacin for four days at a dose of 6 mg/kg i.p. urinary protein excretion was significantly (P < 0.001) reduced (67.52 19.49 after the treatment v. 221 61 mg/day before the treatment, Fig. 3 ). The reduction of proteinuria was associated with an inhibition of TxB2 urinary excretion by 74% (9.57 3.98 after the treatment v. 33.25 5.27 ng/day before the treatment, P < 0.001, Fig. 4) .
Urinary excretion of 6-keto-PGF1, and PGE2 were significantly (P <0.01) reduced in PHN rats after indomethacin treatment (6-keto-PGF1,, 6.81 1.50 after the treatment v.
30. 23 8.70 ng/day before the treatment; PGE2, 10.32 5.58 after the treatment v. 28.82 7.70 ng/day before the treatment).
Effect of a selective Tx-synthase inhibitor on proteinuria and urinary excretion of TxB2
To evaluate whether the favorable effect of indomethacin on proteinuria, presumably due to the fact that indomethacin in this model is effective in reducing the renal synthesis of TxA2, could be also obtained by the use of a selective inhibitor of Tx synthesis, we treated two groups of eight PHN rats with the Tx synthase inhibitor UK-38,485 at the doses of 20 and 40 mg/kg i.p. Proteinuria appeared not to be modified by the Tx-synthase inhibitor irrespective of the dose employed. Figure 3 shows the mean values of proteinuria before, 235 50 mg/day (day 12) and after, 455 152 mg/day (day 16) UK-38,485 treatment at the dose of 20 mg/kg. The latter values were not different from those obtained in a comparable group of rats not given the inhibitor, and studied at the same interval from the anti-gp 330 serum injection (450 129 mg/day). Similar results were obtained in the group of PHN rats treated with 40 mg/kg of UK-38,485. Proteinuria was 226 80 mg/day before (day 12) and 432 149 mg/day alter (day 16) the treatment. After the administration of 20 mg/kg of UK-38,485 urinary TxB2 excretion was reduced by 43% (19.71 5.14 ng/day in PHN rats after UK-38,485 treatment v. 34 7.63 ng/day in the same animals before the treatment, P <0.01; Fig. 4) . A comparable effect on TxB2 urinary excretion rate was found with the higher dose of UK-38,485 we used. TxB2 excretion was reduced by 44% (19.62 4.27 ng/day in the same animals before the treatment). 8.1 nglday in the same rats before the treatment.
Renal function studies in rats with PHN given UK-38,485 or indomethacin In order to establish whether the reduction of urinary protein excretion observed in PHN rats after indomethacin treatment could be related to an impairment of renal function, we measured serum creatinine at the end of the experimental period (Fig. 5) . The mean value of serum creatinine of PHN rats studied 16 days after anti-gp 330 serum injection was not Figure 5 shows that two out of eight PHN rats given indomethacin had an increase in serum creatinine (1.22 and 1.28 mgldl, respectively) at the end of the four days treatment, whereas in the remaining animals given indomethacin serum creatinine levels were not different from controls (0.68 0.06 mg/dl). No differences have been observed in the degree of reduction of proteinuria between the two animals with renal insufficiency as compared to the six animals which did not develop renal failure, suggesting that the reduction of proteinuria in this group of animals is unlikely to be the consequence of an impaired renal function. Since serum creatmine may not be an absolute indicator for GFR we also 39 mg/day before the treatment).
Discussion
The results of the present study show that indomethacin at a dose of 6 mg/kg i.p. administered to rats with PHN induced by anti-gp 330 serum effectively reduces urinary protein excretion. The reduction in proteinuria does not appear to be a consequence of a reduction in GFR since both serum creatinine and inulin clearance were not modified in PHN animals given indomethacin or the vehicle. The antiproteinuric effect of indomethacin in our study is consistent with the results obtained by Kirschenbaum, Liebross and Serros [22] who studied the effect of indomethacin on proteinuria in another model of Heymann nephritis induced in rats by the administration of autologous tubular FxlA antigen. These authors considered the possibility that indomethacin induces structural changes in podocytes [231, re-establishing the integrity of glomerular filtration barrier. However, they were unable to find changes in the structure of glomerular visceral epithelial cells after examining indomethacin or vehicle treated animals by electron microscopy. To clarify if the favorable effect of indomethacin on proteinuria could be attributed to the drug's inhibitory effect on the PG-forming enzyme cyclooxygenase, Kirschenbaum et al [22] studied the urinary excretion of PGE in animals with Heymann nephritis treated with indomethacin. They found that indomethacin significantly inhibited urinary PGE excretion, but a simple relationship between this phenomenon and the antiproteinuric effect of the drug was challenged by the observation that sodium salicylate, despite inhibiting PGE to comparable extent, did not influence protein excretion. This argument prompted the authors to consider it unlikely that the antiproteinuric effect of indomethacin is mediated by an inhibitory effect on PG synthetic pathway. However, the urinary PGE is primarily of medullary origin and therefore it might not be the best marker for evaluating the effect of a drug purposed to inhibit the synthesis of eicosanoids at cortical level.
The possibility that indomethacin favorably influences proteinuria by inhibiting the synthesis of eicosanoids at cortical level is consistent with recent findings. A relationship between proteinuria and altered glomerular metabolism of AA has been demonstrated in several experimental models of glomerular damage. Using a model of nephrotoxic nephritis in rats Lianos, Andres and Dunn [24] observed an increased synthesis of TxB2, the stable breakdown product of TxA2, by isolated glomeruli, which linearly correlated with the extent of proteinuria. No correlation has been found between 6-keto-PGF1. and PGE2 urinary excretion and proteinuria, indicating that the cyclooxygenase metabolite which can play a contributory role in the pathophysiology of proteinuria is likely to be Tx rather than vasodilatory PGs. Our group has reported a significant increase of both glomerular synthesis and urinary excretion of TxB2 in rats with ADR nephrosis [25] . 6-keto-PGF1a and PGE2 urinary excretion were not modified. These results suggest that AA metabolism can be altered in glomerular disease, the most consistent finding being a selective increase in the renal synthesis of TxA2 that is reflected in an increased urinary excretion of TxB2.
In PHN we have found that glomerular production of TxB2, but not of 6-keto-PGF1,,, and PGE2 is increased in the Our present data cannot rule out the possibility that other actions of indomethacin [reviewed in 271, independently of the cyclooxygenase inhibition, are responsible for the antiproteinuric effect of this drug. Despite the fact that the present data do not implicate that TxA2 can cause proteinuria, if one considers together the present results, those obtained by Lianos, Andres and Dunn [24] and by Purkerson et al [28] it is tempting to suggest an association between the antiproteinuric effect of the different molecules used and their activity in suppressing TxB2 urinary excretion. It is possible that when the glomerular membrane is already damaged by a disease process an increase in TxA2 is one of the factors contributing to the loss of charge or size selectivity properties. However we cannot exclude that urinary excretion of TxB2 is only a marker of other system(s) activation more directly responsible for amplifying the damage of the filtering membrane. Similarly our present results do not completely rule out the possibility that the increased urinary excretion of TxB2 in PHN is a consequence of proteinuria. As far as the cause of the increased renal Tx synthesis in PHN, it has to be mentioned that PHN is associated with complement activation, and that recent evidence has become available as to indicate that complement activation may interfere with AA metabolism leading to an increase in PG and Tx formation. In particular, incubation of terminal complement components with cultured glomerular epithelial cells induces a statistically significant release in PGE and TxB2 [29] .
In conclusion, our present results together with those of Kirschenbaum, Liebross and Serros [22] provide the experimental basis for the clinical observation of Michielsen and Lambert [I] , and indicate that the antiproteinuric effect of indomethacin can be observed without a concomitant reduction in renal function. The efforts in finding more selective molecules with antiproteinuric effect have to be pursued given the consideration that the presence of proteinuria is associated with a rapid progression in most glomerular diseases. In this context, studies are needed to identify compounds more selective than indomethacin to be used in experimental animals and humans with nephrotic syndrome in order to obtain a reduction in proteinuria.
